ORIGINAL ARTICLE  VENOUS DISEASE Editor’s choice • Open access

International Angiology 2023 February;42(1):37-44

DOI: 10.23736/S0392-9590.22.04970-7

Copyright © 2022 THE AUTHORS

This is an open access article distributed under the terms of the CC BY-NC 4.0 license which allows users to distribute, remix, adapt and build upon the manuscript, as long as this is not done for commercial purposes, the user gives appropriate credits to the original author(s) and the source (with a link to the formal publication through the relevant DOI), provides a link to the license and indicates if changes were made.

language: English

Recurrences and bleeding during extended treatment of patients with venous thromboembolism: results of the international, prospective, observational WHITE study

Gualtiero PALARETI ¹ ✉, Victor BARINOV ², Tomasz URBANEK ³, Michela CINI ¹, Young-Jun LI ⁴, Kamel BOUSLAMA ⁵, Jiří MATUŠKA ⁶, Armando MANSILHA ⁷, Juraj MADARIC ⁸, German Y. SOKURENKO ⁹, Giuseppe M. ANDREOZZI ¹⁰ on behalf of the WHITE study group

¹ Arianna Anticoagulazione Foundation, Bologna, Italy; ² Central State Medical Academy of the Office of the President of the Russian Federation, Volynskaya Clinical Hospital N.1, Moscow, Russia; ³ Medical University of Silesia, Katowice, Poland; ⁴ Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; ⁵ Faculty of Medicine of Tunis, Tunis, Tunisia; ⁶ Clinical Trial Centre, Hodonin, Czechia; ⁷ Faculty of Medicine, University of Porto, Porto, Portugal; ⁸ Clinic of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia; ⁹ North-West Mechnikov State Medical University, St. Petersburg, Russia; ¹⁰ Unit of Angiology, University of Padua, Padua, Italy

BACKGROUND: Little data are available on real-life long-term treatments after a venous thromboembolism (VTE), and on recurrent VTE or bleeds events during treatments.
METHODS: We investigated the complications occurring during follow-up (FU) in VTE patients who had received the treatment decisions given by the clinical centers, active in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, Tunisia), which participated in the international, prospective, observational WHITE study.
RESULTS: FU information was collected in 1004 patients, recruited by 62 clinical centers (17 centers did not participate in FU collection). Extended treatments were proposed to 811 patients: direct oral anticoagulants (DOACs) (475), sulodexide (202), antiplatelet agents (73), vitamin K antagonists (VKAs) (45), low molecular weight heparin (LMWH) (16). All specific treatments were stopped in the remaining 193 patients. Patients who during FU used treatments different than those prescribed by the local investigators (263) or for other causes (26) were excluded from analysis. 50 primary events occurred throughout 1044 years FU in 715 patients, 4.8 incidence (×100 patient-years) [3.8 for recurrences, and 0.96 for bleeding (major or clinically relevant)]. Primary event incidence differed according to treatments (LMWH=33.3, antiplatelets =7.6, VKAs = 6.1, DOACs = 4.7, sulodexide = 4.2, all treatment stopped = 2.5), and differed across the involved countries.
CONCLUSIONS: DOACs were the most used drugs for extended treatments. Overall, the rate of primary events during FU was low. The investigators identified patients at low risk of recurrence and high bleeding risk. Sulodexide use for secondary prevention deserves further studies.

KEY WORDS: Venous thromboembolism; Therapeutics; Factor Xa inhibitors; Platelet aggregation inhibitors